Ratings Beximco Pharmaceuticals Limited London S.E.

Equities

Market Closed - London S.E. Other stock markets 16:35:26 17/05/2024 BST			5-day change	1st Jan Change
40.5 ^GBX	0.00%		+3.85%	-2.41%

04-30	EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	AN
04-30	Beximco Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	CI

The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
Analysts covering this company mostly recommend stock overweighting or purchase.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Analyst opinion has improved significantly over the past four months.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

	1st Jan change	Capi.	ESG Refinitiv
BEXIMCO PHARMACEUTICALS LIMITED	-2.41%	452M	-
ELI LILLY AND COMPANY	+32.09%	693B	C+
NOVO NORDISK A/S	+29.39%	584B	B
JOHNSON & JOHNSON	-1.34%	372B	C+
MERCK & CO., INC.	+20.34%	332B	B-
ABBVIE INC.	+7.39%	294B	C+
ASTRAZENECA PLC	+14.25%	239B	B+
ROCHE HOLDING AG	-3.03%	211B	A+
NOVARTIS AG	+10.02%	210B	B-
AMGEN INC.	+8.49%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality